Essa Pharma Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Essa Pharma Reports Q2 Loss Per Share $0.36
Brief: ESSA Pharma Says Clinical Study Is Expected To Start In 2021 For Combination Of EPI-7386 And Darolutamide
Brief: Essa Pharma Announces Clinical Collaboration With Astellas